Abstract
BackgroundBullous pemphigoid is the most common bullous chronic autoimmune skin disease. Recent studies have suggested dipeptidyl-peptidase 4 inhibitors as possible predisposing agents of bullous pemphigoid. The objective of our study was to prospectively estimate the association between gliptins and the development of bullous pemphigoid.MethodsWe conducted a prospective study which included all patients diagnosed with biopsy-proven bullous pemphigoid in the Dermatology Department of our hospital between April 1, 2009 and December 31,2019. The diagnosis of bullous pemphigoid was based on specific clinical, histological and immunological features.ResultsOverall 113 consecutive patients (age 75 ± 13 years, 62 females) with the diagnosis of bullous pemphigoid were enrolled. Seventy-six patients (67.3%) suffered from type 2 Diabetes and 52 (46%) were treated with dipeptidyl-peptidase 4 inhibitors. The most frequent prescribed gliptin was vildagliptin, being administered to 45 cases (39.8% of total patients enrolled, 86.5% of the patients treated with gliptins). Gliptins were withdrawn immediately after the diagnosis of bullous pemphigoid, which together with steroid administration led to remission of the rash.ConclusionsThis study revealed that treatment with dipeptidyl-peptidase 4 inhibitors, especially vildagliptin, is significantly associated with an increased risk of bullous pemphigoid development.
Highlights
Bullous pemphigoid is the most common bullous chronic autoimmune skin disease
The most frequent prescribed Dipeptidyl peptidase 4 (DPP4)-i was vildagliptin, being administered to 45 cases (39.8% of total patients enrolled, 86.5% of the patients treated with Dipeptidyl peptidase 4 inhibitor (DPP4-i))
This study suggests that treatment with DPP4-is, especially vildagliptin in this specific Greek population, are significantly associated with an increased risk of Bullous pemphigoid (BP) development
Summary
Recent studies have suggested dipeptidyl-peptidase 4 inhibitors as possible predisposing agents of bullous pemphigoid. Bullous pemphigoid (BP) is the most common chronic bullous autoimmune skin disease which is characterized by the presentation of subepidermical blisters. It is considered as a disease of the elderly people and is associated with significant morbility and mortality [1]. Recent studies have suggested that dipeptidyl peptidase-4 inhibitors (DPP4-is), an incretin-based drug for type 2 diabetes, as possible predisposing agents of BP [2, 3]. The objective of our study was to estimate the association between the use of DPP4-is and the development of BP in the setting of a tertiary university hospital and to raise awareness for everyday clinical practice, both among dermatologists as well as all physicians following patients with diabetes
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
